Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease
- PMID: 19640010
- DOI: 10.2165/00019053-200927060-00003
Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease
Abstract
Background: There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases.
Objective: This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a societal perspective.
Methods: We developed 16 COPD health profiles. Each profile combined a description of the severity of COPD during the stable phase with a description of the exacerbation profile in terms of severity, frequency and duration. These profiles were valued by a representative sample of 239 Dutch adults using the visual analogue scale (VAS) and time trade-off (TTO) methods. Value functions were estimated using random effects regression analysis.
Results: Both VAS and TTO values consistently decreased as severity of the COPD profiles increased. Estimated TTO values ranged from 0.97 for mild COPD without exacerbations to 0.43 for very severe COPD with one non-serious and one serious exacerbation per year. The estimated decrements in TTO values ranged from 0.010 for having one non-serious exacerbation to 0.088 for having one non-serious plus one serious exacerbation per year.
Conclusions: The value function may be an alternative way to model the joint impact of COPD severity and exacerbations on utility values in health economic modelling studies.
Similar articles
-
Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals.Health Qual Life Outcomes. 2015 Mar 13;13:34. doi: 10.1186/s12955-015-0228-2. Health Qual Life Outcomes. 2015. PMID: 25889281 Free PMC article.
-
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.Pharmacoeconomics. 2005;23(6):619-37. doi: 10.2165/00019053-200523060-00008. Pharmacoeconomics. 2005. PMID: 15960557
-
Impact of mild exacerbation on COPD symptoms in a Japanese cohort.Int J Chron Obstruct Pulmon Dis. 2016 Jun 9;11:1269-78. doi: 10.2147/COPD.S105454. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27354785 Free PMC article.
-
Exacerbations of chronic obstructive pulmonary disease.Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5. Respir Care. 2003. PMID: 14651761 Review.
-
Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis.Value Health. 2016 Jun;19(4):363-73. doi: 10.1016/j.jval.2016.01.012. Epub 2016 Mar 24. Value Health. 2016. PMID: 27325328 Review.
Cited by
-
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22500119 Free PMC article.
-
Utility estimation in chronic obstructive pulmonary disease: a preference for change?Pharmacoeconomics. 2011 Nov;29(11):917-32. doi: 10.2165/11589280-000000000-00000. Pharmacoeconomics. 2011. PMID: 21988291
-
"Back to the future": Influence of beliefs regarding the future on TTO answers.Health Qual Life Outcomes. 2016 Jan 12;14:4. doi: 10.1186/s12955-015-0402-6. Health Qual Life Outcomes. 2016. PMID: 26753687 Free PMC article.
-
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30. Int J Chron Obstruct Pulmon Dis. 2013. PMID: 23386787 Free PMC article.
-
Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.Pharmacoeconomics. 2017 Dec;35(12):1237-1255. doi: 10.1007/s40273-017-0554-9. Pharmacoeconomics. 2017. PMID: 28776320 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical